Physician profile
Paula Bryant Barnett
NPI 1164516449
$5,666.36
in general payments reported to CMS, 2019-2025
36 companies · $1,152 in 2025
The $1,152 reported for 2025 was more than what 97% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $598 · 2022: $792 · 2023: $2,311 · 2024: $814 · 2025: $1,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,276.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,341.81 | 2021-2025 | |
| Dexcom, INC. | $392.97 | 2023-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Mayne Pharma Commercial LLC | $311.99 | 2022-2023 | |
| Daiichi Sankyo INC. | $309.11 | 2021-2024 | Injectafer |
| Astellas Pharma US INC | $267.00 | 2023 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $266.85 | 2022-2024 | |
| Corcept Therapeutics | $226.50 | 2024-2025 | Korlym |
| Novo Nordisk INC | $216.58 | 2023-2025 | Ozempic, Wegovy |
| Abbott Laboratories | $185.88 | 2023-2024 | Freestyle Libre 3, Thoratec Heartmate 3 Lvas Implant Kit |
| Teva Pharmaceuticals USA, INC. | $184.58 | 2022-2023 | Austedo |
| Exeltis, USA INC. | $142.30 | 2023 | Slynd |
| Cvrx, INC. | $137.80 | 2025 | Barostim Neo System |
| Acella Pharmaceuticals, LLC | $130.01 | 2023 | NP Thyroid 60 |
| Genzyme Corporation | $127.37 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $121.13 | 2024 | Uptravi, Opsumit |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $115.75 | 2025 | Vyvgart |
| Alkermes, INC. | $114.75 | 2023 | Lybalvi |
| Paratek Pharmaceuticals, INC. | $113.72 | 2025 | Nuzyra |
| Sanofi Pasteur INC. | $103.47 | 2025 | |
| Abiomed | $102.96 | 2023 | Impella |
| Hologic Sales and Service, LLC | $94.61 | 2021-2024 | Thinprep 2000 Processor, Aptima |
| Pfizer INC. | $86.46 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $85.43 | 2024 | |
| Mylan Pharmaceuticals INC. | $70.12 | 2021 | |
| Coopersurgical, INC. | $69.50 | 2021-2025 | Paragard T 380a, Paragard T 380a |
| Idorsia Pharmaceuticals US INC | $62.40 | 2023 | Quviviq |
| Shield Therapeutics INC | $53.05 | 2023-2024 | Accrufer |
| Therapeuticsmd, INC. | $38.79 | 2021-2022 | |
| Evofem Biosciences, INC. | $38.18 | 2022 | |
| Scynexis, INC. | $37.52 | 2022 | |
| Medtronic, INC. | $30.70 | 2024 | Venaseal |
| Vapotherm INC | $20.51 | 2023 | Vapotherm |
| Agile Therapeutics, INC. | $20.33 | 2021 | |
| Avion Pharmaceuticals | $16.49 | 2023 | Balcoltra |
| Organon LLC | $15.87 | 2023 | Nexplanon |
| Sage Therapeutics, LLC | $13.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Bryant Barnett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.